Catalyst Monitor: Q4 2026 Outlook

This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q4 2026.

GlobalData's latest report, "Catalyst Monitor Q4 2026", delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, Phase III trial results, PDUFA dates, and regulatory filings. The report covers 26 significant catalyst events that are expected to occur in Q4 2026.

Some of the catalysts covered in the report, include approval decisions for Genentech's giredestrant in breast cancer, Sun Pharmaceutical Industries' tildrakizumab in psoriatic arthritis and Summit Therapeutics' ivonescimab in non-small cell lung cancer.

Additionally, experts also discuss expectations about the ongoing clinical trials such as Exelixis' Phase III trial in non-clear cell renal cell carcinoma (nccRCC), NewAmsterdam Pharma's Phase III trial results in cardiovascular disease and more.

The Catalyst Monitor report is published on a quarterly basis. The data presented in this report reflects the database as of 11 September.

Scope

• The Q4 Catalyst Monitor report offers exclusive forward-looking insights on Phase III results, regulatory drug approvals and more, based on exhaustive research and exclusive KOL interviews.

Reasons to Buy

This report will enable the user to answer the following questions:

• Which biopharma companies are expecting major milestones such as FDA decisions or late-stage trial completions and results in Q4 2026?
• Which upcoming regulatory catalysts that are expected in Q4 2026 are likely to be market-moving events?
• How do the number of expected regulatory events like trial initiations and trial completions in Q4 2026 compare to the previous quarter?
• Which are the top therapy areas for market-moving catalysts in Q4 2026 compared to the previous quarter?
• Which companies have the highest numbers of upcoming catalysts expected in Q4 2026?
• What approval decision do experts project for Summit Therapeutics' ivonescimab in non-small cell lung?
• What are the expectations regarding Exelixis's Phase III trial results in non-clear cell renal cell carcinoma (nccRCC)?
• How do KOLs assess the approval prospects of Genentech's two PDUFAs for giredestrant in breast cancer?